# Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration

> **NCT02944227** · PHASE4 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 20 (actual)

## Conditions studied

- Wet Macular Degeneration

## Interventions

- **DRUG:** Lucentis

## Key facts

- **NCT ID:** NCT02944227
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-03
- **Primary completion:** 2017-02-16
- **Final completion:** 2017-08-21
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02944227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02944227, "Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02944227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*